Company intelligence / Profile preview

ZymIQ Biopharma

Ownership: Private
Development stage: Preclinical

Overview

ZymIQ has developed enzyme-based antimicrobial solutions with two technology platforms. The "Protect" platform creates a barrier against bacterial growth by targeting bacterial adhesion, while the "Combat" platform uses enzymes to target difficult bacterial infections while preserving the healthy microbiome. Recent news indicates they've secured orders within NATO for their Combat Clean product for military oral health[9].

Therapeutic areas: Infectious Diseases
Modalities: Enzyme-based therapeutics
Industry: Biotech

Drug pipeline

2 assets

Mycolyse

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Lund University

Beyond the preview

Go deeper on ZymIQ Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZymIQ Biopharma.

Explore the full profile